Business
Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® (inclisiran) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), significantly increasing the risk of early cardiovascular events such as heart attack and stroke.1
About this update from Novartis Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. ","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":162,"olType":false},{"type":"text","content":"MONTRÉAL, Aug. 21, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® (inclisiran) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), significantly increasing the risk of early cardiovascular events such as heart attack and stroke.1","length":523,"tagName":"p"},{"type":"image","alt":"Novartis Pharmaceuticals Canada Inc. logo (CNW Group/Novartis Pharmaceuticals Canada Inc.)","displaySize":"","headline":null,"caption":"Novartis Pharmaceuticals Canada Inc. logo (CNW Group/Novartis Pharmaceuticals Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":143,"url":"https://media.zenfs.com/en/cnwgroup.com/55dce7395576088b787abaec3c22d23e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C5zvWkQzc5HrF2XIgVo49g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/55dce7395576088b787abaec3c22d23e","width":400,"height":143}},"href":"https://mma.prnewswire.com/media/2754703/Novartis_Pharmaceuticals_Canada_Inc__Leqvio__advances_toward_bro.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""At HeartLife, we believe that people living with FH deserve timely access to the most effective therapies available," said Marc Bains, Co-Founder, HeartLife Foundation. "This agreement is an important step forward in closing long-standing gaps in care and expanding treatment options for patients who face a significantly higher risk of early heart disease. We are committed to working with partners across Canada to ensure these advances reach the people who need them most."","length":497,"tagName":"p"},{"type":"text","content":""Familial Hypercholesterolemia is underdiagnosed and undertreated, despite the significant cardiovascular ris...